Brokers Issue Forecasts for Journey Medical FY2027 Earnings

Key Points

• B. Riley has reduced its FY2027 earnings per share (EPS) estimate for Journey Medical from $1.33 to $1.16, while the consensus estimate remains at ($1.02) per share.
• The company reported a quarterly EPS of (0.16), falling short of analysts' expectations of (0.07), despite revenue surpassing expectations at $15.01 million.
• Journey Medical has received mixed ratings from analysts, with Alliance Global Partners retaining a "buy" rating and Wall Street Zen downgrading to "hold."

Journey Medical Corporation (NASDAQ:DERM - Free Report) - Stock analysts at B. Riley cut their FY2027 EPS estimates for Journey Medical in a research note issued to investors on Wednesday, August 13th. B. Riley analyst M. Mamtani now forecasts that the company will earn $1.16 per share for the year, down from their previous forecast of $1.33. The consensus estimate for Journey Medical's current full-year earnings is ($1.02) per share. B. Riley also issued estimates for Journey Medical's FY2028 earnings at $1.98 EPS.

Several other analysts have also recently issued reports on DERM. Lake Street Capital upped their price target on shares of Journey Medical from $9.00 to $13.00 and gave the company a "buy" rating in a report on Wednesday, August 13th. Wall Street Zen lowered shares of Journey Medical from a "buy" rating to a "hold" rating in a research note on Sunday, July 6th. Zacks Research lowered shares of Journey Medical from a "hold" rating to a "strong sell" rating in a research note on Friday, August 15th. Finally, Alliance Global Partners reiterated a "buy" rating on shares of Journey Medical in a research note on Thursday, May 15th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Journey Medical currently has an average rating of "Moderate Buy" and a consensus target price of $10.83.

Journey Medical Price Performance

DERM remained flat at $7.07 during trading on Friday. 102,342 shares of the company traded hands, compared to its average volume of 109,777. The company has a market cap of $164.73 million, a P/E ratio of -18.61 and a beta of 0.80. The stock has a fifty day moving average of $7.14 and a 200-day moving average of $6.56. The company has a current ratio of 1.27, a quick ratio of 0.95 and a debt-to-equity ratio of 1.11. Journey Medical has a 1 year low of $3.54 and a 1 year high of $8.90.

Journey Medical (NASDAQ:DERM - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.09). The company had revenue of $15.01 million during the quarter, compared to analyst estimates of $14.93 million. Journey Medical had a negative net margin of 15.49% and a negative return on equity of 48.69%.

Hedge Funds Weigh In On Journey Medical

Several institutional investors have recently modified their holdings of DERM. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Journey Medical during the second quarter worth about $29,000. Bank of America Corp DE grew its position in shares of Journey Medical by 4,707.0% during the second quarter. Bank of America Corp DE now owns 4,134 shares of the company's stock worth $30,000 after acquiring an additional 4,048 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Journey Medical during the second quarter worth about $36,000. JPMorgan Chase & Co. bought a new position in shares of Journey Medical during the second quarter worth about $41,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Journey Medical during the second quarter worth about $48,000. Institutional investors own 7.25% of the company's stock.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.